Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04747431
Other study ID # PBFT02-001
Secondary ID 2020-004499-17
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 14, 2021
Est. completion date August 2027

Study information

Verified date April 2024
Source Passage Bio, Inc.
Contact Patient/Family Inquiries
Phone 267-866-0113
Email patientservices@passagebio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with frontotemporal dementia and mutations in the progranulin gene (FTD-GRN).


Description:

PBFT02 is an adeno-associated viral vector serotype 1 carrying GRN, the gene encoding for human progranulin, formulated as a solution for injection into the cisterna magna. This is a global interventional, multicenter, open-label, single-arm, dose-escalation study of PBFT02 delivered as a one-time dose administered into the cisterna magna to patients with FTD-GRN. Subjects aged ≥ 35 and ≤ 75 years with early symptomatic FTD-GRN may be enrolled into the study. Two dose levels of PBFT02 will be studied in patients with FTD-GRN. The study will sequentially enroll 2 cohorts. An optional third dose level cohort may be enrolled based on the results of the first two cohorts. This is a 5-year study, with a 2-year main study, followed by a 3-year safety extension.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date August 2027
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 35 Years to 75 Years
Eligibility Inclusion Criteria: 1. Documented to be a pathogenic GRN mutation carrier 2. Clinical diagnosis of frontotemporal dementia 3. Have a reliable informant / caregiver (and back-up informant / caregiver) who personally speaks with or sees the subject at least weekly 4. Living in the community (i.e., not in a nursing home); assisted living may be permitted at the discretion of the investigator Exclusion Criteria: 1. Classification of the GRN mutation as "not pathogenic," "likely benign variant," "benign variant," or "pathogenic nature unclear" 2. Previous treatment with any gene therapy. Any other therapies with the potential to alter PGRN levels must be washed out for at least 5 half-lives prior to entry into this study 3. Homozygous GRN mutation carrier 4. Rosen-modified Hachinski Ischemic Scale score > 7 5. Known presence of a structural brain lesion (eg, tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic subject 6. Known presence of an AD-causing mutation in PSEN1, PSEN2 or APP based on genetic testing history (if performed) 7. Previous history of Korsakoff encephalopathy, severe alcohol or substance dependence (within 5 years of onset of dementia), except where onset of increased alcohol consumption occurs at the time of FTD disease onset 8. History of untreated vitamin B12 deficiency 9. Presence of untreated hypothyroidism (thyroid stimulating hormone [TSH] > ULN and free T4 < LLN) 10. eGFR = 30 ml/min (as calculated using the CKD-EPI equation) 11. Alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 2 × ULN, or total bilirubin > ULN) 12. Respiratory failure that requires supplemental oxygen 13. Inability to provide full consent or the lack of a legally authorized caregiver with adequate contact who can provide consent 14. Any contraindication to MRI or lumbar puncture (LP) (eg, local infection, history of thrombocytopenia, coagulopathy) 15. Any contraindication to the ICM administration procedure 16. Medical conditions or laboratory or vital sign abnormalities that would increase risk of complications from intra-cisterna magna injection, anesthesia, LP, and/or MRI (e.g., fever, hypoxia, tachycardia, or evidence of active infection) 17. Immunocompromised status 18. Peripheral axonal sensory neuropathy 19. Receipt of a vaccine within 14 days of dosing 20. A positive test result for human immunodeficiency virus (HIV), human T cell leukemia virus (HTLV) type 1 or type 2, or Hepatitis B or C; a Mycobacterium tuberculosis positive test within 1 year of or determined at screening 21. Malignant neoplasia (except localized skin cancer) or a documented history of hereditary cancer syndrome 22. Any concurrent disease that, in the opinion of the investigator, may cause cognitive impairment unrelated to GRN mutations, including other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin deficiency 23. Current or recent history of clinically significant suicidal ideation within the past 6 months 24. For females of childbearing potential, a positive serum pregnancy test at the screening visit, a positive serum result on Day 1 prior to administration of the investigational product, or unwillingness to have additional pregnancy tests during the study. Females of childbearing potential must use a highly effective method of birth control or engage in abstinence until 90 days postdose 25. Women who are breastfeeding 26. For sexually active men, unwillingness to use a medically accepted method of double-barrier contraception (such as a condom/diaphragm used with spermicide) or engage in abstinence from the date of screening until 90 days postdose 27. Any condition (eg, history of any disease, evidence of any current disease, any finding upon physical examination, or any laboratory abnormality) that, in the opinion of the investigator, would put the subject at undue risk or would interfere with evaluation of the investigational product or interpretation of subject safety or study results 28. Any acute illness requiring hospitalization within 30 days of enrollment 29. Failure to meet the protocol-specified coagulation test criteria: - Platelet count over 100,000 per uL - INR less than 1.5 - aPTT less than 40 seconds 30. Use of anticoagulants in the 2 weeks prior to screening, or anticipated use of anticoagulants during the study. Antiplatelet therapies may be acceptable 31. Hypersensitivity or contraindications to corticosteroid use 32. Known or suspected intolerance or hypersensitivity to PBFT02 or any of its ingredients or to closely related compounds

Study Design


Intervention

Drug:
PBFT02
PBFT02

Locations

Country Name City State
Brazil Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG) Minas Gerais
Brazil Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP) São Paulo
Canada Montreal Neurological Institute-Hospital Montréal Quebec
Canada University of Toronto, Toronto Western Hospital Toronto Ontario
Italy Besta Institute Milan
Portugal Centro Hospitalar e Universitário de Coimbra Coimbra
United States University of Texas at Houston Houston Texas
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Passage Bio, Inc.

Countries where clinical trial is conducted

United States,  Brazil,  Canada,  Italy,  Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Treatment-Related AEs and SAEs Assess the number of treatment-related adverse events (AEs) and serious adverse events (SAEs) Up to 5 years (multiple visits)
Primary Change in Nerve Conduction Velocity from Baseline on Nerve Conduction Studies Assess changes in nerve conduction velocity in the distal segments of the sural, radial, and median sensory nerves and peroneal motor nerve as measured on conventional nerve conduction studies. From baseline to 5 years (multiple visits)
Primary Change in Nerve Conduction Amplitude from Baseline on Nerve Conduction Studies Assess changes in nerve conduction amplitude in the distal segments of the sural, radial, and median sensory nerves and peroneal motor nerve as measured on conventional nerve conduction studies. From baseline to 5 years (multiple visits)
Primary Assess Humoral Response Against the Vector and Transgene in Serum Assess serum antibody titers against AAV1 and against progranulin following ICM administration of PBFT02 Up to 5 years (multiple visits)
Primary Assess Humoral Response Against the Vector and Transgene in CSF Assess antibody titers in the cerebrospinal fluid against AAV1 and against progranulin following ICM administration of PBFT02 Up to 5 years (multiple visits)
Secondary Change from baseline in FTD clinical domains as assessed by the Clinical Dementia Rating National Alzheimer's Coordinating Center frontotemporal lobar degeneration domains (CDR Plus NACC FTLD) Assess changes in cognitive, behavioral and language domains using the CDR Plus NACC FTLD From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using the Multilingual Naming Test (MINT). From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using the Number Span Test From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using Verbal Fluency From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using Semantic Fluency From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using the Trail Making Test A and B From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using California Verbal Learning Test (CVLT) From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using the Benson Complex Figure Copy (immediate and delayed recall) From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using the Montreal Cognitive Assessment (MoCA) From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using the Frontotemporal Dementia Rating Scale (FRS) From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using the Cambridge Behavioral Inventory - Revised (CBI-R) From baseline to 2 years (multiple visits)
Secondary Change from baseline in neurocognitive and other assessments Assess changes using the Clinical Global Impression of Severity and Change (CGI-S, CGI-C) From baseline to 2 years (multiple visits)
Secondary Change in Biomarkers of Progranulin Levels in Plasma Assess change in progranulin levels in plasma when compared with baseline From baseline to 2 years (multiple visits)
Secondary Change in Biomarkers of Progranulin Levels in CSF Assess change in progranulin levels in CSF when compared with baseline From baseline to 2 years (multiple visits)
Secondary Change in Concentration of Biomarkers of Disease Progression in Plasma Assess changes in neurofilament light chain (NfL) concentration and glial fibrillary acidic protein (GFAP) as markers for neurodegeneration and disease progression in plasma From baseline to 2 years (multiple visits)
Secondary Change in Concentration of Biomarker of Disease Progression in CSF Assess change in neurofilament light chain concentration (NfL) as a marker for neurodegeneration and disease progression in CSF From baseline to 2 years (multiple visits)
Secondary Change in Ocular Biomarkers of Disease Progression Assess changes in retinal thickness and retinal lipofuscin assessed by optical coherence tomography as markers of disease progression From baseline to 2 years (multiple visits)
Secondary Change in Brain Anatomy as Assessed by MRI Assess change in brain volume by MRI imaging From baseline to 2 years (multiple visits)
Secondary Change in Brain Anatomy as Assessed by MRI Assess change in cortical thickness by MRI imaging From baseline to 2 years (multiple visits)
Secondary Change in Brain Anatomy as Assessed by MRI Assess change in white matter integrity by MRI imaging From baseline to 2 years (multiple visits)
Secondary Change in Activities of Daily Living Scales Assess change in activities of daily living as measured by the Schwab and England Activities of Daily Living Scale From baseline to 2 years (multiple visits)
Secondary Change in Activities of Daily Living Scales Assess change in activities of daily living as measured by the Functional Activities Questionnaire From baseline to 2 years (multiple visits)
Secondary Change in Survival Assess change in vital status From baseline to 2 years (multiple visits)
See also
  Status Clinical Trial Phase
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Active, not recruiting NCT03987295 - A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Phase 2
Withdrawn NCT05497817 - A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia N/A
Recruiting NCT04918251 - EEG and TMS-based Biomarkers of ALS, MS and FTD
Completed NCT01002300 - Oxytocin and Social Cognition in Frontotemporal Dementia N/A
Completed NCT01890343 - Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Phase 2
Completed NCT00376051 - Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Phase 4
Terminated NCT00159198 - Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1
Active, not recruiting NCT04516499 - Neurofilament Surveillance Project (NSP)
Completed NCT03636204 - A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation Phase 1
Completed NCT01937013 - Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Phase 2
Active, not recruiting NCT05075187 - Epidemiological Study in FRONtoTemporal Dementia
Not yet recruiting NCT05004558 - Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias N/A
Completed NCT02999282 - Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects N/A
Completed NCT00594737 - Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Phase 3
Recruiting NCT03225144 - Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Active, not recruiting NCT04993755 - A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD Phase 2
Recruiting NCT04114994 - Longitudinal Cognitive Assessment by BoCA
Recruiting NCT04408625 - Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) Phase 1/Phase 2